AnaptysBio, Inc.

AnaptysBio, Inc. (Nasdaq: ANAB) is a San Diego, United States company that exclusively manages the financial collaborations from Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their value to stockholders. It operates a virtual operating model with fewer than approximately 10 FTEs operating as contractors to support the essential functions of a public company, and anticipates annualized operating expenses of less than $10 million and a greater than 95% EBIT margin. Anaptys completed the spin-off of First Tracks Biotherapeutics, its biotech operations, on April 20, 2026.

AnaptysBio, Inc. (Nasdaq: ANAB) is a company in San Diego, United States. It exclusively manages the financial collaborations from Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their value to stockholders. Anaptys completed the spin-off of First Tracks Biotherapeutics, its biotech operations, on April 20, 2026. Daniel Faga has served as Anaptys' president and chief executive officer since March 2022. Christopher M. Murphy joined AnaptysBio in May 2026 as chief financial officer. In May 2026, Anaptys announced the appointment of Christopher Murphy as Chief Financial Officer and Owen Hughes as a member of its Board of Directors.

Strategic stewardship of financial collaborations to deliver shareholder value

1. 1Home - Anaptys Royalty Coanaptysbio.com
2. 2About Us - Anaptys Royalty Coanaptysbio.com
3. 3AnaptysBio, Inc. (United States)wikidata.org